Drug intelligence / Profile preview

Shuanglong Baoxin

Development stage: Unknown
Lead developer: Xiangxue Pharmaceutical
Administration: Oral

Overview

Shuanglong Baoxin is a traditional Chinese medicine (TCM) formulation developed by Xiangxue Pharmaceutical for the treatment of coronary heart disease. It is currently in Phase 1 clinical development. As a multi-component herbal therapy, it is designed to address cardiovascular symptoms associated with coronary heart disease, although its specific molecular targets and pharmacological mechanisms have not been detailed in public clinical disclosures. The drug is formulated as an oral tablet.

Brand names: Shuanglong Baoxin Tablet
Other names: 双龙保心片

Targets

CYP2B6 (Cytochrome P450 2B6)ABCG2 (Breast cancer resistance protein)CYP2C19 (Cytochrome P450 2C19)OATP1B1 (Organic anion transporting polypeptide 1B1)

Beyond the preview

Go deeper on Shuanglong Baoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuanglong Baoxin.

Explore the full profile